For decades, allergists and immunologists have prioritized topical treatments - like inhaled or nasal steroids, intranasal antihistamines, and topical steroids and calcineurin inhibitors - to minimize the risks associated with systemic steroids such as prednisone.
These localized approaches work well for many patients but fall short in severe or complex conditions like severe asthma, nasal polyps, extensive atopic dermatitis, hereditary angioedema (HAE), chronic spontaneous urticaria (CSU), or cases with multiple comorbid allergic diseases that demand broader, systemic impact.
Advances in molecular understanding of allergic and immunologic disorders have paved the way for a new era: highly targeted systemic therapies, including biologics and small-molecule inhibitors. These precision medicines attack specific pathways with impressive efficacy and far better safety profiles than traditional systemic options.
There are emerging systemic options for asthma and allergies, including repurposed drugs, novel targets (e.g., TSLP receptor, IL-33 axis, OX40 ligand), and even unconventional approaches like GLP-1 agonists or medium-chain triglycerides.
HAE management is shifting from outdated therapies to modern prophylactic and on-demand options - now including oral plasma kallikrein inhibitors, novel monoclonal antibodies, and hepatocyte-targeted antisense oligonucleotides.
Kinase inhibitors (e.g., JAK, BTK, KIT) selectively block key signaling in mast cells, type 2 cytokines, and more, marking a new frontier for urticaria and atopic dermatitis.
CSU treatments are advancing from anti-IgE (omalizumab) to kinase inhibitors and emerging targets like MRGPRX2 and Siglec.
Evidence-based algorithm for atopic dermatitis in children and adults includes biologics (IL-4/IL-13/IL-31 pathways) and JAK inhibitors.
These targeted systemic therapies represent a game-changer, enabling precise, multi-organ treatment for chronic, debilitating conditions with reduced side effects. As the field evolves, further research into disease heterogeneity and biomarkers will refine their use even more.
Clinicians now have powerful, accessible resources in this issue to transform patient care - moving from symptom management to true disease modification. The future of allergy and immunology is here, and it's more targeted than ever.
References:
https://www.jaci-inpractice.org/article/S2213-2198(25)01185-7/fulltext